Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Van Hout

Showing results (21-30 of 115) with videos related to

Pageof 12
Sort By:
Pharmacoeconomics|January 19, 2006
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.
Health Economics|January 29, 2005
Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertaintyMaiwenn J Al, Talitha L Feenstra, Ben A van Hout
Nederlands Tijdschrift Voor Geneeskunde|February 13, 1993
[Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome]B A Van Hout, F F Rutten, R H Lorijn
Pharmacoeconomics|January 19, 2006
Modelling the impact of compliance on the costs and effects of long-acting risperidone in CanadaP S Chue, Bart Heeg, Erik Buskens, et al.
The Journal of Cardiovascular Surgery|March 31, 2006
The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysisE Buskens, M J Meijboom, H Kooijman, et al.
Pharmacoeconomics|March 12, 2003
The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximationBen A van Hout, Dennis D Gagnon, Pauline McNulty, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 9, 2004
[Sepsis, a complicated syndrome with major medical and social consequences]J Bakker, M Levi, B A van Hout, et al.
BMJ Open|June 11, 2015
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the diseaseStephanie Stephens, Marc F Botteman, Mary A Cifaldi, et al.
European Heart Journal|May 23, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Journal of Medical Genetics|October 10, 1997
Cost effectiveness of DNA diagnosis for four monogenic diseasesA A van der Riet, B A van Hout, F F Rutten
Pageof 12

Showing results (21-30 of 115) with videos related to

Sort By:
Pageof 12
Pharmacoeconomics|January 19, 2006
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in GermanyGerd Laux, Bart Heeg, Ben A van Hout, et al.
Health Economics|January 29, 2005
Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertaintyMaiwenn J Al, Talitha L Feenstra, Ben A van Hout
Nederlands Tijdschrift Voor Geneeskunde|February 13, 1993
[Cost-effectiveness analysis of human monoclonal antibody HA-1A in patients with sepsis syndrome]B A Van Hout, F F Rutten, R H Lorijn
Pharmacoeconomics|January 19, 2006
Modelling the impact of compliance on the costs and effects of long-acting risperidone in CanadaP S Chue, Bart Heeg, Erik Buskens, et al.
The Journal of Cardiovascular Surgery|March 31, 2006
The use of a surgical sealant (CoSeal) in cardiac and vascular reconstructive surgery: an economic analysisE Buskens, M J Meijboom, H Kooijman, et al.
Pharmacoeconomics|March 12, 2003
The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximationBen A van Hout, Dennis D Gagnon, Pauline McNulty, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 9, 2004
[Sepsis, a complicated syndrome with major medical and social consequences]J Bakker, M Levi, B A van Hout, et al.
BMJ Open|June 11, 2015
Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the diseaseStephanie Stephens, Marc F Botteman, Mary A Cifaldi, et al.
European Heart Journal|May 23, 1998
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic ComplicationsB A van Hout, L Bowman, D J Zelinger, et al.
Journal of Medical Genetics|October 10, 1997
Cost effectiveness of DNA diagnosis for four monogenic diseasesA A van der Riet, B A van Hout, F F Rutten
Pageof 12